Clinical trials: Malignancies Multiple
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
This phase II trial studies how well tacrolimus and mycophenolate mofetil works in preventing graft-versus-host disease in patients who have undergone total-body irradiation (TBI) with or without fludarabine phosphate followed by…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00089011
- Testing
- fludarabine phosphate, total-body irradiation, mycophenolate mofetil
- Where
- 5 sites in United States, Italy
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Role of BCL-B in Multiple Myeloma
MM accounts for 10% of hematopoietic malignancies. Despite the use of various drug combinations in chemotherapy, life expectancy of MM patients does not exceed 7 years.
- Trial name
- NCT01270009
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Multiple Myeloma
A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma
The purpose of this study is to see if using the radioactive tracer 89Zr-DFO-daratumumab with PET/CT scans is a practical and effective way to view and monitor multiple myeloma in participants before and during their treatment…
- Trial name
- NCT04467281
- Testing
- 89Zr-DFO-daratumumab, PET/CT
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Plasma Cell Myeloma
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when given together with dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement.
- Trial name
- NCT01711528
- Testing
- Bortezomib, Dexamethasone, Dinaciclib
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Obesity, Colorectal Cancer
Prevention of Obesity-related Cancers: Setting up of a Multi-Cancer Education and Prevention Program in Hong Kong
Obesity could increase the risk of many chronic diseases, including hypertension, cardiovascular diseases, high lipid level, diabetes, stroke, endometrial cancer and certain types of cancer which could benefit by secondary…
- Conditions
- Obesity, Colorectal Cancer, Prostate Cancer, Breast Cancer
- Trial name
- NCT04034953
- Testing
- Faecal Immunochemical Test, Prostate-Specific Antigen Test, Mammogram
- Where
- Hong Kong
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Colorectal Cancer, Metastasis
A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer
To investigate whether intraoperative intraportal chemotherapy combined with adjuvant chemotherapy as treatment could improve disease-free survival (DFS) in patients with curative colorectal cancer resection compared with…
- Trial name
- NCT02402972
- Testing
- FUDR +oxaliplatin, oxaliplatin+Leucovorin+5-FU
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Xu jianmin
Multiple Myeloma
A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients
The primary reason for this study is to further assess safety and efficacy data of the bortezomib/melphalan/prednisone (BMP) regimen in previously untreated and transplant ineligible multiple myeloma patients
- Trial name
- NCT00799539
- Testing
- bortezomib, melphalan, prednisone
- Where
- 3 sites in Canada
- Sponsor
- Janssen-Ortho Inc., Canada
Advanced Solid Tumors
First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and to determine the maximum tolerable dose (MTD) and/or recommended phase 2 dose (RP2D) of HH30134 administered orally on a continuous…
- Trial name
- NCT04746612
- Testing
- HH30134
- Where
- 4 sites in Australia, China
- Volunteers
- 22 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Solid Tumor, Adult
Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors
Multiple solid tumors have positive targets of mesothelin expressed on the surfaces of the tumor cells, the investigators use the technique of CRISPR-Cas9 to knocked out the PD-1 of the chimeric antigen receptor (CAR) T cells…
- Trial name
- NCT03747965
- Testing
- Mesothelin-directed CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese PLA General Hospital
Colorectal Cancer Liver Metastasis
FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis
The investigators plan to initiate a prospective, multicenter, phase II study, recruiting 30 patients with advanced colorectal cancer patients with liver metastasis who have not received prior treatment.
- Trial name
- NCT06801665
- Testing
- FMT+QL1706+Bevacizumab+XELOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hua Jiang
Plasma Cell Myeloma
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Primary Objective: -To demonstrate the benefit of isatuximab in combination with bortezomib, lenalidomide, and dexamethasone in the prolongation of progression free survival (PFS) as compared to bortezomib, lenalidomide, and…
- Trial name
- IMROZ (NCT03319667)
- Testing
- Isatuximab SAR650984, Bortezomib, Lenalidomide
- Where
- 104 sites in United States, Australia and 19 more
- Volunteers
- 475 people
- Sponsor
- Sanofi
Thyroid Nodules
The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules
The incidence rates of thyroid cancers have increased in the past decade. Additionally, up to 68% of people have thyroid nodules.
- Trial name
- NCT02937467
- Testing
- SWE
- Sponsor
- Peking University Cancer Hospital & Institute
Chemotherapy-induced Thrombocytopenia, Romiplostim N01
Romiplostim N01 for Chemotherapy-induced Thrombocytopenia
To evaluate the efficacy and safety of Romiplostim N01 to treat chemotherapy-induced thrombocytopenia in tumors
- Trial name
- NCT07063225
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Refractory, Multiple Myeloma
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
The purpose of this study is to assess the safety/tolerability and determine the Japanese recommended dose (RD) of bortezomib administered as a once-daily intravenous bolus twice weekly for 2 consecutive weeks(Days 1, 4, 8, and…
- Conditions
- Refractory, Multiple Myeloma, Relapse
- Trial name
- NCT00752518
- Testing
- bortezomib
- Volunteers
- 35 people
- Sponsor
- Janssen Pharmaceutical K.K.
Lung Cancer, Squamous Cell Carcinoma
An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037
Phase: Exploratory Study Objectives: To collect drug bio-distribution data, begin collection of baseline and tumor/background imaging data, acquire experience to improve study design and the conduct of future studies Design…
- Conditions
- Lung Cancer, Squamous Cell Carcinoma, Head and Neck Cancer, Hepatic Carcinoma
- Trial name
- VM4-037 (NCT00884520)
- Testing
- [F-18] VM4-037
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Siemens Molecular Imaging
Breast Ductal Carcinoma In Situ
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients with HER2 expressing ductal carcinoma in situ.
- Trial name
- NCT04144023
- Testing
- Granulocyte-Macrophage Colony-Stimulating Factor, Multi-epitope HER2 Peptide Vaccine H2NVAC, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Mayo Clinic
Rheumatoid Arthritis, Atherosclerotic Ischemic Disease
Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study
The Coronary Computed Tomography Angiography in Rheumatoid Arthritis study is part of the multinational, prospective, observational Autoimmunity and Atherosclerosis in Rheumatic Diseases cohort (https://atacc-rd.com) that…
- Conditions
- Rheumatoid Arthritis, Atherosclerotic Ischemic Disease, Pulmonary Disease, Depressive Disorder
- Trial name
- COTIRA (NCT07363980)
- Where
- 4 sites in Denmark
- Volunteers
- 4,000 people
- Sponsor
- Ellen Margrethe Hauge
Colorectal Neoplasms, Colonic Polyps
A Novel Clinical Decision Support Tool to Predict Submucosal Invasive Cancer Within Large Non-Pedunculated Colorectal Polyps
Colorectal cancer can be effectively prevented by removal of pre-malignant polyps during colonoscopy. Large (>=20mm) non-pedunculated colorectal polyps (LNPCPs) require careful assessment before treatment.
- Trial name
- NCT07705880
- Where
- Belgium
- Volunteers
- 886 people
- Sponsor
- University Hospital, Ghent
Unspecified Adult Solid Tumor, Protocol Specific
A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors
The purpose of this study is to determine the Maximum Tolerated Dose and the Dose-Limiting Toxicity of the drug to further evaluate safety and antitumor activity.
- Trial name
- NCT01631279
- Testing
- PR610
- Where
- 6 sites in United States, New Zealand
- Volunteers
- 33 people
- Sponsor
- Proacta, Incorporated
Advanced Solid Tumor, Metastatic Cancer
FIH XON7 in Advanced/Metastatic Solid Tumors
This is a two-stage trial consisting of a Part I, dose escalation and dose-finding component to establish the Maximal Tolerated Dose (MTD), if any, and Recommended Part 2 Dose (RP2D) of XON7, followed by a Part II component to…
- Trial name
- FIPO23 (NCT06154291)
- Testing
- XON7
- Where
- 5 sites in Belgium, France
- Volunteers
- 255 people
- Sponsor
- Xenothera SAS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.